Compare iShares Global Tech ETF (IXN) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Tech ETF vs Novartis AG — how do they compare? iShares Global Tech ETF trades at $139.33, while Novartis AG trades at $152.33 (market cap $295.37B). The key difference: Novartis AG pays a 3.07% dividend while iShares Global Tech ETF pays none, and iShares Global Tech ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| IXN | NVS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $149.74 | $168.62 |
52-Week Low | $94.42 | $119.31 |
Market Cap | — | $295.37B |
Enterprise Value | — | $336.69B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IXN trades at $140.87, up 1.09% today, with a bullish technical signal from moving averages. The stock is near resistance at $141, with RSI indicating potential overbought conditions. Recent news highlights its global tech exposure, including AI developments from international firms.
Outlook is cautious due to high valuations and concentration risk in tech holdings. Opportunities exist from AI growth, but risks include stretched earnings expectations and market volatility. Analyst sentiment is mixed, favoring a hold rating for a better entry point.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Global Tech ETF
IXN provides exposure to global electronics, software, and hardware companies. It tracks the S&P Global 1200 Information Technology Index, covering tech leaders across both developed and emerging markets.
Read more on IXN →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
